Yahoo Web Search

Search results

  1. For more than two decades, Charles Stiefel actively demonstrated his unwavering commitment to the Foundation, and support of researchers in dermatology. As a member of the Leaders Society, Annenberg Circle, and the Fitzpatrick Legacy Fund, Charles Stiefel contributed to dermatology’s continual advancement, as did Stiefel Laboratories.

  2. View Charles Stiefels profile on LinkedIn, the world’s largest professional community. Charles has 10 jobs listed on their profile.

    • 500+
    • 2.3K
    • Yale Cancer Center Discovery Fund
    • Raleigh, North Carolina, United States
  3. Jul 31, 2023 · Charles Werner Stiefel was born on October 30, 1950, in Catskill, NY to Werner K. Stiefel and Catherine Pierson Stiefel. He died peacefully of multiple illnesses on July 31, 2023, surrounded by family in Raleigh, NC.

    • Raleigh, NC
    • (919) 876-6900
  4. Aug 19, 2023 · Under Charlie’s leadership, Stiefel Laboratories developed, patented, and distributed dermatology products in more than 100 countries and was considered the largest independent manufacturer of dermatological products. Charlie's published book, Skin Saga, recounts Stiefel Laboratories and Stiefel family stories.

  5. Aug 19, 2023 · Chairman and CEO (2001) of Stiefel Laboratories, Inc. The origin of Stiefel Laboratories dates back to 1847 in Germany, and Charlie was the sixth gener-ation Stiefel to lead the company. Charlie led the company until it’s sale to GlaxoSmithKline (2009). Under Charlie’s leadership, Stiefel Laboratories developed, patented, and ...

  6. The SEC alleged that Stiefel Laboratories and Charles Stiefel used artificially low valuations for stock buybacks and failed to disclose information that would have alerted employee shareholders their stock was worth much more than the price the company paid them.

  7. Jun 5, 2020 · The SEC alleged that Stiefel Laboratories and Charles Stiefel used artificially low valuations for stock buybacks and failed to disclose information that would have alerted employee shareholders their stock was worth much more than the price the company paid them.